Bandingkan Harga & Kinerja Capitalinc Investment Tbk. (MTFN) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Capitalinc Investment Tbk. dan Organon Pharma Indonesia Tbk.: Capitalinc Investment Tbk. diperdagangkan di Rp13 (kapitalisasi pasar 413,95 M, volume 24 jam 21,34 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Capitalinc Investment Tbk. jauh lebih besar — sekitar 4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MTFN | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 413,95 M | 104,4 M |
Volume | 21,34 jt | — |
Lot | 213,43 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Capitalinc Investment Tbk.
PT Capitalinc Investment Tbk formerly PT Bakrie Finance Corporation Tbk hereinafter called the Company was established based on deed No.15 dated November 11, 1993 of Notary Soedarno, SH. The deed of establishment was approved by the Minister of Justice of the Republic of Indonesia in his decree No. C2.7999-HT.01.01.Th.83 dated December 12, 1983 and was published in the State Gazette of the Republic of Indonesia No.4 dated January 13, 1984, Supplement No.35.Before the amendment in its articles of association, the scope of its activities include leasing, factoring receivable and consumer financing. The Company obtained its operating license as a financial institution from the Minister of Finance of the Republic of Indonesia through decree No.295/KMK.013/1990 dated March 3, 1990. In line with the change in the Company’s scope of activities, the Company’s financing activities have been transferred to PT Swadinamika Bakrie Finance, a subsidiary.
Selengkapnya di halaman MTFN →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
